SAN RAFAEL, Calif., Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia. These results, as well as data from the investigational research program for VOXZOGO in hypochondroplasia, were presented at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting in Liverpool, England, Nov. 16-18, 2024. "The extensiv

WASHINGTON, Nov. 16, 2024 /PRNewswire/ -- Physicians are learning how to better support the needs of people with rheumatoid arthritis (RA) from online search trends, according to a new study from researchers at Hospital for Special Surgery (HSS) and colleagues at Columbia University Vagelos College of Physicians & Surgeons. The study examined how patients engage with the digital world using real-time data from Google Trends. The patterns reveal not only how rheumatoid conditions affect daily lif

In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agencies INDIANAPOLIS, Nov. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepati

REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue will be featured in an oral session at ACR Converge

SATURDAY, Nov. 17, 2024 -- As the holidays approach, most folks are familiar with a common side effect of the overindulgence that can come with all those meals with family and friends: Bloating. Luckily, Baylor College of Medicine gastroenterologist Dr. David Szafron has some tips on what triggers bloating, what kinds of foods are big triggers for it and when you need to see a doctor. First, bloating is defined as a feeling of trapped gas in the abdomen, fullness or abdominal pressure, Szafron

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here . President-elect Donald Trump made good on his pledge to let Robert F. Kennedy Jr. “go wild on health,” nominating him as HHS secretary. For more on what this will mean for biopharma, read below, and keep checking back at Endpoints where our reporter

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 25th Annual Meeting of the Society of Urologic Oncology (SUO) taking pla

The Agreement, Established as Part of Governor Ron DeSantis' Trade Mission to Italy, Makes Tampa General Hospital the First Health System in the Southeastern United States to Offer Robotic-Assisted Lymphatic Microsurgery. MILAN, Nov. 15, 2024 /PRNewswire/ -- Tampa General Hospital and the University of South Florida announced today an agreement with Medical Microinstruments, Inc., or MMI, to bring the Symani Surgical System, a first-of-its-kind robotic technology, to support lymphatic surgery at

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of rel

TORONTO, Nov. 15, 2024 /PRNewswire/ - Greenbrook TMS Inc. (OTC: GBNHF) (" Greenbrook" or the " Company") is pleased to announce that the Company has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement in accordance with the Business Corporations Act (Ontario) (the " Arrangement"). Pursuant to the terms of the Arrangement, Neuronetics, Inc. (" Neuronetics") will acquire all of the issued and outstanding common